In a groundbreaking initiative poised to revolutionize cancer treatment, AstraZeneca announces a strategic $300 million investment in a cutting-edge facility in Rockville, Maryland. This visionary move aims to catapult AstraZeneca's life-saving cell therapy platforms into critical cancer trials and future commercial supply in the US, promising hope for patients worldwide.

The newly unveiled facility, nestled within Maryland's burgeoning life sciences corridor, will be a beacon of innovation, focusing initially on manufacturing T-cell therapies to drive pivotal clinical trials across the globe. Over 150 new highly skilled positions will be forged, igniting a wave of opportunities in the region's scientific community.

Pam Cheng, Executive Vice President of Global Operations & IT and Chief Sustainability Officer at AstraZeneca, exclaimed, "We are on the brink of transformation, poised to bring groundbreaking therapies to the forefront of clinical trials, potentially altering the course of patient care worldwide. This $300 million investment underscores our unwavering commitment to advancing next-generation cell therapy and meeting the urgent needs of patients."

Nestled in the heart of Maryland's vibrant life sciences ecosystem, the Rockville facility stands as a testament to AstraZeneca's dedication to fostering innovation and collaboration. With its strategic location near leading research institutions and universities, the facility is primed to attract top-tier talent, driving forward the boundaries of scientific discovery.

Maryland Governor Wes Moore hailed the partnership, stating, "AstraZeneca's visionary investment underscores Maryland's position as a global leader in life sciences innovation. This transformative endeavor will not only bolster our state's competitive edge but also solidify our commitment to advancing groundbreaking therapies that save lives. We extend our deepest gratitude to AstraZeneca for their steadfast partnership and investment in our state."

The Rockville facility joins AstraZeneca's expansive global network of manufacturing and supply sites, reinforcing the company's commitment to delivering innovative medicines to patients worldwide. With a focus on small molecules and biologics, AstraZeneca's US manufacturing sites play a pivotal role in driving pharmaceutical excellence, employing over 2,600 dedicated professionals and delivering over 9 billion doses of medicines annually.

AstraZeneca's bold investment in Maryland's cutting-edge facility marks a transformative milestone in the journey towards revolutionizing cancer treatment, offering a beacon of hope to patients and underscoring the company's unwavering commitment to pioneering medical breakthroughs